- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Knight Therapeutics Inc (GUD)
Knight Therapeutics Inc stock price live, this page displays TSX GUD stock exchange data. View the GUD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Knight Therapeutics Inc real time stock price chart below.
What Is the Knight Therapeutics Inc Stock Price Today?
The Knight Therapeutics Inc stock price today is 5.76.
What Is the Stock Symbol for Knight Therapeutics Inc?
The stock symbol for Knight Therapeutics Inc is "GUD."
What Stock Exchange Does Knight Therapeutics Inc Trade On?
Knight Therapeutics Inc is listed and trades on the Toronto stock exchange.
Is Knight Therapeutics Inc a Good Stock to Buy?
Determining whether Knight Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GUD quote. (ISIN: CA4990531069)
What Is the Knight Therapeutics Inc Stock Price Today?
The Knight Therapeutics Inc stock price today is 5.76.
What Is the Stock Symbol for Knight Therapeutics Inc?
The stock symbol for Knight Therapeutics Inc is "GUD."
What Stock Exchange Does Knight Therapeutics Inc Trade On?
Knight Therapeutics Inc is listed and trades on the Toronto stock exchange.
Is Knight Therapeutics Inc a Good Stock to Buy?
Determining whether Knight Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GUD quote. (ISIN: CA4990531069)
5.76
0.00(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.75
5.80
52 wk Range
5.09
6.45
GUD Scorecard
Full Analysis
Management has been aggressively buying back shares
GUD is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.755.80
52 wk Range
5.096.45
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
GUD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
7.91
Upside
+37.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Knight Therapeutics Inc Company Profile
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson’s disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson’s disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, the company finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
Knight Therapeutics Inc Earnings Call Summary for Q1/2025
- Knight Therapeutics beats Q1 2025 EPS forecast with $0.02 vs -$0.0007, revenue at $88M, up 3% YoY
- Adjusted EBITDA down 11% YoY to $12.1M; company maintains strong financial health with perfect Piotroski Score
- 2025 revenue guidance: $390M-$405M; Adjusted EBITDA expected at 13% of revenues
- Paladin acquisition on track for mid-2025, expected to enhance product portfolio and cash flow generation
- Stock slightly down 0.33% post-earnings despite beat, closing at $6.07
Last Updated: 08/05/2025, 11:16 pm
Read Full TranscriptCompare GUD to Peers and Sector
Metrics to compare | GUD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGUDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 51.9x | −0.3x | −0.4x | |
PEG Ratio | 0.32 | 0.00 | 0.00 | |
Price/Book | 0.7x | 1.0x | 2.6x | |
Price / LTM Sales | 1.5x | 1.0x | 2.9x | |
Upside (Analyst Target) | 34.5% | 12.4% | 53.5% | |
Fair Value Upside | Unlock | 22.2% | 9.5% | Unlock |
Analyst Ratings
6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 7.91
(+37.30% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
0.02 / -0.0007
Revenue / Forecast
87.98M / 87.71M
People Also Watch
FAQ
What Is the Knight Therapeutics Inc (GUD) Stock Price Today?
The Knight Therapeutics Inc stock price today is 5.76
What Stock Exchange Does Knight Therapeutics Inc Trade On?
Knight Therapeutics Inc is listed and trades on the Toronto Stock Exchange stock exchange.
What Is the Stock Symbol for Knight Therapeutics Inc?
The stock symbol for Knight Therapeutics Inc is "GUD."
What Is the Knight Therapeutics Inc Market Cap?
As of today, Knight Therapeutics Inc market cap is 573.85M.
What Is Knight Therapeutics Inc's Earnings Per Share (TTM)?
The Knight Therapeutics Inc EPS (TTM) is 0.11.
When Is the Next Knight Therapeutics Inc Earnings Date?
Knight Therapeutics Inc will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is GUD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Knight Therapeutics Inc Stock Split?
Knight Therapeutics Inc has split 0 times.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.